# A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

> **NCT03500380** · PHASE2,PHASE3 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 301 (estimated)

## Conditions studied

- Breast Neoplasms
- Breast Diseases
- Capecitabine
- HER2-positive Breast Cancer
- HER2 Positive Breast Carcinoma
- HER2-positive Advanced Breast With Liver Metastases

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** Lapatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03500380
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-24
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 301 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03500380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03500380, "A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03500380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*